Patient Conversations: Setting the Stage for Positive Multifocal IOL Outcomes


Educating patients on what they’ll experience before and after cataract surgery gives them the knowledge and confidence to proactively manage their experience and their mindset, driving positive outcomes. Explore the tabs below to learn more.


Streamlining the Multifocal IOL Patient Journey: Customizing Vision

The patient journey is the progression from the initial diagnosis and referral to your practice to cataract surgery and recovery. Proper management of this journey by you and your staff can help ensure your patients are satisfied with the process and with their multifocal IOLs. Click/Hover over? each step in the patient journey graphic below for tips about enhancing your patients’ experience.

Once cataracts have been diagnosed and patients have been referred to your practice, prepare them for their appointment by mailing or emailing them educational materials. Include a welcome letter introducing yourself and your practice, and describe other educational tools available to them.

The pre-op measurement process presents an excellent opportunity for your staff to educate patients on the types of IOLs available to them. It should be patient friendly, promoting a relaxed environment and helping patients make a more informed decision upon your recommendation.

If you decide that the patient is a good multifocal candidate, make a clear recommendation and outline the benefits and limitations of the IOL you’re recommending, setting appropriate expectations.

Designating a member of your staff to discuss the specifics of multifocal lens pricing with patients can relieve pressure on you, allowing you to make a confident recommendation regardless of cost.

After your recommendation, send patients home with educational materials to review. Their lens choice should be reinforced by your staff as part of routine reminders and information given prior to the procedure.

As part of your assessment immediately after surgery, patients should be reminded that visual disturbances, such as halos, glare, flare and blurred near vision, especially in dim light conditions, may occur during the recovery process but will generally subside over time.1

Even if you manage your patients' pre- and post-op expectations well, some patients may still express unhappiness with their initial outcome. Pay extra attention to these patients and show them that you and your practice are dedicated to working toward an optimal outcome.

Managing Multifocal IOL Patient Expectations

Proper expectations, satisfied patients

Multifocal lenses can offer excellent benefits, especially when there are multiple add powers to meet specific patient needs. But these lenses will likely come with side effects as well. Managing expectations will help patients maintain a positive outlook while they adapt to their new lenses.

Watch Dr. Stephen Scoper set realistic, positive expectations for optimal multifocal IOL outcomes and the adjustment process that accompanies implantation.

Watch Dr. Stephen Scoper set realistic, positive expectations for optimal multifocal IOL outcomes and the adjustment process that accompanies implantation.
Watch Dr. Stephen Scoper set realistic, positive expectations for optimal multifocal IOL outcomes and the adjustment process that accompanies implantation.

Remind your patients about the challenges

AcrySof® IQ ReSTOR® Multifocal IOLs are designed to help customize a patient's vision based on needs, lifestyle, vision goals and adaptability. The critical time for patients to evaluate their vision is a few months after implantation, when their brain has had time to adjust to the change.1

Because of the structure of multifocal lenses, they do not exactly replicate natural lens function, particularly in low-light conditions. Therefore, patients may be challenged by their perceptive change, similar to adapting to new eyeglasses.

Visual disturbances fade over time

The majority of patients reported very few problems with visual disturbances six months after having multifocal IOLs implanted in both eyes.

It’s also key to remind your patients that:

  • It may be necessary to have another procedure to treat certain levels of astigmatism after surgery.
  • In a clinical study, it took the majority of patients implanted with AcrySof® IQ ReSTOR® +3.0 D IOLs about six months after surgery to achieve distance vision of 20/25 or better without glasses.1
  • They may initially see some glare and halos around lights at night early after surgery. This typically diminishes over the next few months.1
  • In general, for AcrySof® IQ ReSTOR® IOLs, most patients reported a low occurrence of visual disturbances like halos and glare.1,2
  • Continued vision correction (reading glasses, for example) may be needed at times.
X
View Important Product Information for
AcrySof® IQ ReSTOR® Family of IOLs +

ACRYSOF® IQ RESTOR® FAMILY OF INTRAOCULAR LENSES IMPORTANT PRODUCT INFORMATION

CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician.

INDICATIONS: The AcrySof® IQ ReSTOR® Posterior Chamber Intraocular Lens (IOL) is intended for primary implantation for the visual correction of aphakia secondary to removal of a cataractous lens in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence. The lens is intended to be placed in the capsular bag.

WARNINGS/PRECAUTIONS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Physicians should target emmetropia, and ensure that IOL centration is achieved. Care should be taken to remove viscoelastic from the eye at the close of surgery.

Some patients may experience visual disturbances and/or discomfort due to multifocality, especially under dim light conditions. As with other multifocal IOLs, visual symptoms may be significant enough that the patient will request explant of the multifocal IOL. Spectacle independence rates vary with all multifocal IOLs; as such, some patients may need glasses when reading small print or looking at small objects.

Clinical studies with the AcrySof® ReSTOR® lens indicated that posterior capsule opacification (PCO), when present, developed earlier into clinically significant PCO. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon for this product informing them of possible risks and benefits associated with the AcrySof® IQ ReSTOR® IOLs.

Studies have shown that color vision discrimination is not adversely affected in individuals with the AcrySof® Natural IOL and normal color vision. The effect on vision of the AcrySof® Natural IOL in subjects with hereditary color vision defects and acquired color vision defects secondary to ocular disease (e.g., glaucoma, diabetic retinopathy, chronic uveitis, and other retinal or optic nerve diseases) has not been studied. Do not resterilize; do not store over 45° C; use only sterile irrigating solutions such as BSS® or BSS PLUS® Sterile Intraocular Irrigating Solutions.

ATTENTION: Reference the Directions for Use labeling for a complete listing of indications, warnings and precautions.

Click here to view the AcrySof® IQ ReSTOR® +2.5 D IOL Directions for Use (DFU).

Click here to view the AcrySof® IQ ReSTOR® +3.0 D IOL Directions for Use (DFU).

ACRYSOF® IQ RESTOR® FAMILY OF INTRAOCULAR LENSES IMPORTANT PRODUCT INFORMATION

CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician.

INDICATIONS: The AcrySof® IQ ReSTOR® Posterior Chamber Intraocular Lens (IOL) is intended for primary implantation for the visual correction of aphakia secondary to removal of a cataractous lens in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence. The lens is intended to be placed in the capsular bag.

WARNINGS/PRECAUTIONS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Physicians should target emmetropia, and ensure that IOL centration is achieved. Care should be taken to remove viscoelastic from the eye at the close of surgery.

Some patients may experience visual disturbances and/or discomfort due to multifocality, especially under dim light conditions. As with other multifocal IOLs, visual symptoms may be significant enough that the patient will request explant of the multifocal IOL. Spectacle independence rates vary with all multifocal IOLs; as such, some patients may need glasses when reading small print or looking at small objects.

Clinical studies with the AcrySof® ReSTOR® lens indicated that posterior capsule opacification (PCO), when present, developed earlier into clinically significant PCO. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon for this product informing them of possible risks and benefits associated with the AcrySof® IQ ReSTOR® IOLs.

Studies have shown that color vision discrimination is not adversely affected in individuals with the AcrySof® Natural IOL and normal color vision. The effect on vision of the AcrySof® Natural IOL in subjects with hereditary color vision defects and acquired color vision defects secondary to ocular disease (e.g., glaucoma, diabetic retinopathy, chronic uveitis, and other retinal or optic nerve diseases) has not been studied. Do not resterilize; do not store over 45° C; use only sterile irrigating solutions such as BSS® or BSS PLUS® Sterile Intraocular Irrigating Solutions.

ATTENTION: Reference the Directions for Use labeling for a complete listing of indications, warnings and precautions.

Click here to view the AcrySof® IQ ReSTOR® +2.5 D IOL Directions for Use (DFU).

Click here to view the AcrySof® IQ ReSTOR® +3.0 D IOL Directions for Use (DFU).